We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 51

House, Senate approve FDA User FeeDrug Safety Bills
  • Reed Smith LLP
  • USA
  • May 31 2012

On May 30, 2012, the House of Representatives voted 387-5 to approve H.R. 5651, the Food and Drug Administration Reform Act


FDA reports on post-approval drug safety monitoring
  • Reed Smith LLP
  • USA
  • May 11 2012

According to an April 24, 2012 Center for Drug Evaluation and Research (CDER) report, a strengthened and modernized post-market drug safety program has resulted in a substantial improvement in FDA’s oversight of drugs once they reach the American public


FDA issues final rule on sterility testing of biological products
  • Reed Smith LLP
  • USA
  • May 11 2012

On May 3, 2012 the FDA issued its final rule on sterility testing, amending the requirements for most licensed biological products effective June 4, 2012


Overview and analysis of the proposed federal sunshine
  • Reed Smith LLP
  • USA
  • January 30 2012

On December 19, 2011, the Centers for Medicare & Medicaid Services published a proposed rule related to section 6002 of the Affordable Care Act, commonly referred to as the “Physician Payment Sunshine Act”


FDA guidance on product name placement in advertising and promotional labeling
  • Reed Smith LLP
  • USA
  • January 25 2012

The FDA released a guidance document entitled ‘‘Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling’’ on January 25, 2012


OIG examines how Part D limits drugs to medically-accepted indications
  • Reed Smith LLP
  • USA
  • November 29 2011

According to a recent OIG report, “Ensuring That Medicare Part D Reimbursement Is Limited to Drugs Provided for Medically Accepted Indications,” Medicare Prescription Drug Plan sponsors do not have access to information necessary to ensure that Medicare Part D reimbursement is limited to drugs provided for medically-accepted indications (e.g., uses approved by Food and Drug Administration and supported by one or more of three specified compendia


Congressional health policy hearings & markups
  • Reed Smith LLP
  • USA
  • November 11 2011

A number of Congressional committees have held hearings recently on health policy issues


Preparing for Round 2 of the DMEPOS competitive bidding program
  • Reed Smith LLP
  • USA
  • September 1 2011

As discussed in our August 18, 2011 Special Alert, CMS has announced the product categories and specific competitive bidding areas (CBAs) for Round 2 of the Medicare DME, prosthetics, orthotics and supplies (DMEPOS) competitive bidding program


CMS proposes DME minimum lifetime standard
  • Reed Smith LLP
  • USA
  • July 18 2011

As part of the July 8 ESRD PPS proposed rule, CMS included a proposal to revise the definition of durable medical equipment (DME) by adding a 3-year minimum lifetime criterion that must be met by an item or device in order to be considered "durable" for the purpose of classifying the item under the Medicare DME benefit category


GAO issues report on FDA oversight of medical device recalls
  • Reed Smith LLP
  • USA
  • June 28 2011

On June 14, 2011, the GAO released a report entitled "Medical Devices: FDA Should Enhance Its Oversight of Recalls."